Technology | November 29, 2007

Bayer Opens New Door to Contrast Media Safety

Bayer Healthcare Pharmaceuticals responded to concerns by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on administering contrast agents by previewing at RSNA 2007 VistaTrak, a password protected contrast media cabinet that tracks media stock using RFID labels.

Designed to help meet JCAHO regulations on safety, the cabinet can be interfaced with an electronic medical record (EMR), PACS/RIS and billing system to access patient data and monitor for allergic reactions. The monitoring system is designed to help prevent the potential risk of nephrogenic systemic fibrosis (NSF) when a patient is injected with gadolinium-containing contrast agents for magnetic resonance imaging (MRI). The company’s MAGNEVIST (gadopentetate dimeglumine) contrast agent will be the first product to carry the RFID tag in the VistaTrak cabinet.

The cabinet is also password protected to comply with JCAHO’s requirement for contrast agent cabinets to be kept under lock and key. The cabinet is only accessible by using either a coded badge or a pin code.

Once a bottle is removed, the RFID tag inside of the cabinet reads the lot number, expiration date and other information on the label required by JCAHO. The EMR, PACS/RIS and billing system are updated when a bottle is removed from the cabinet to track the procedure and inventory. VistaTrak will not be commercially available until mid-2008.

November 2007

Related Content

Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...
Osprey Medical and GE Healthcare Launch Acute Kidney Injury Educational Program
News | Angiography | September 25, 2018
September 21, 2018 — Osprey Medical announced a collaboration with GE Healthcare on Osprey’s Be Kind to Kidneys campa
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...
Iron Outperforms Gadolinium as MRI Contrast Agent

Scientists at Rice's Laboratory for Nanophotonics added iron chelates (blue) and fluorescent dye (red) to multi-layered gold nanomatryoshkas to create particles that can be used for disease therapy and diagnostics. The "theranostic" nanoparticles have a core of gold (left) that is covered by silica containing the diagnostic iron and dye, which is covered by an outer shell of gold. The particles are about 20 times smaller than a red blood cell, and by varying the thickness of the layers, LANP scientists can tune the nanomatryoshkas to convert light into cancer-killing heat. (Image courtesy of Luke Henderson/Rice University)

News | Contrast Media | August 22, 2018
Rice University nanoscientists have demonstrated a method for loading iron inside nanoparticles to create magnetic...
Guerbet Partners With Imalogix on Dose Optimization With Artificial Intelligence
News | Radiation Dose Management | August 14, 2018
August 14, 2018 — Guerbet LLC USA announced a commercial partnership with Imalogix, a provider of...
Videos | Contrast Media | August 03, 2018
Lawrence Tanenbaum, M.D., FACR, vice president and director of advanced imaging at RadNet, discusses the latest resea
Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...